- Home
- BGSF vs PRLD Comparison
BGSF vs PRLD Comparison
Compare BGSF & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGSF
- PRLD
- Stock Information
- Founded
- BGSF 2007
- PRLD 2016
- Country
- BGSF United States
- PRLD United States
- Employees
- BGSF N/A
- PRLD N/A
- Industry
- BGSF Professional Services
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- BGSF Consumer Discretionary
- PRLD Health Care
- Exchange
- BGSF Nasdaq
- PRLD Nasdaq
- Market Cap
- BGSF 70.1M
- PRLD 69.1M
- IPO Year
- BGSF N/A
- PRLD 2020
- Fundamental
- Price
- BGSF $3.51
- PRLD $1.61
- Analyst Decision
- BGSF Strong Buy
- PRLD Strong Buy
- Analyst Count
- BGSF 1
- PRLD 3
- Target Price
- BGSF $9.00
- PRLD $4.00
- AVG Volume (30 Days)
- BGSF 182.3K
- PRLD 332.8K
- Earning Date
- BGSF 11-05-2025
- PRLD 10-31-2025
- Dividend Yield
- BGSF 57.47%
- PRLD N/A
- EPS Growth
- BGSF N/A
- PRLD N/A
- EPS
- BGSF N/A
- PRLD N/A
- Revenue
- BGSF $266,615,000.00
- PRLD $7,000,000.00
- Revenue This Year
- BGSF N/A
- PRLD N/A
- Revenue Next Year
- BGSF $3.14
- PRLD N/A
- P/E Ratio
- BGSF N/A
- PRLD N/A
- Revenue Growth
- BGSF 28.60
- PRLD N/A
- 52 Week Low
- BGSF $2.91
- PRLD $0.61
- 52 Week High
- BGSF $8.22
- PRLD $1.91
- Technical
- Relative Strength Index (RSI)
- BGSF 28.98
- PRLD 61.89
- Support Level
- BGSF $3.44
- PRLD $1.16
- Resistance Level
- BGSF $3.67
- PRLD $1.68
- Average True Range (ATR)
- BGSF 0.17
- PRLD 0.16
- MACD
- BGSF 0.01
- PRLD 0.02
- Stochastic Oscillator
- BGSF 11.47
- PRLD 85.85
About BGSF BGSF Inc.
BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. two segments: Property Management and Professional. In the Property Management segment is a provider of office and maintenance talent. The Professional segment provides IT professionals with expertise in SAP, Workday, Peoplesoft, Hyperion, Oracle, One Stream, cyber, project management, managed services, and other IT workforce solutions to client partners on a national basis. The group generates the majority of its revenue from the Professional segment.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.